◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1302

LifeTech Scientific Corporation (1302) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-11

LifeTech Scientific Corporation (1302) operates in the Medical Devices industry and is headquartered in Shenzhen, China with about 1,245 employees. Its market capitalization is roughly CNY 7 billion. In the fiscal year ended 2025-12-31, 1302 reported CNY 1.4B in revenue and CNY 148M in net income.

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally.

Interactive charts & full statements →

1302 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 1.4BCNY 1.3BCNY 1.3BCNY 1.1B
Gross ProfitCNY 1.0BCNY 981MCNY 996MCNY 874M
Operating Income (EBIT)CNY 176MCNY 181MCNY 294MCNY 343M
Net IncomeCNY 148MCNY 222MCNY 263MCNY 325M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1302 Free Cash Flow History

1302 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 5.0BCNY 4.9BCNY 4.7BCNY 3.7B
Total LiabilitiesCNY 1.5BCNY 1.4BCNY 1.4BCNY 769M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1302 viewer.

Other Companies in Medical Devices

← 1301All “0-9” companies1303 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.